造血细胞移植后腺病毒病:日本移植登记分析
该日本登记分析纳入2005至2019年间25233例自体及48380例异基因造血细胞移植(HCT)患者,描述腺病毒(AdV)病的累积发病率、危险因素与结局。自体与异基因HCT后1年AdV病累积发病率在儿童分别为0.18%与1.52%,在成人分别为0.49%与2.99%;诊断后1年生存概率自体HCT为65%、异基因HCT为44%。作者认为现有抗病毒药物疗效欠佳,AdV病仍是挑战,需要更好的抗病毒手段。
要点
- 异基因HCT后AdV病1年累积发病率成人2.99%、儿童1.52%,均高于自体HCT。
- 自体HCT后AdV病危险因素包括年龄≥50岁和淋巴瘤。
- 异基因HCT后危险因素包括年龄≥50岁、男性、淋巴瘤、HCT特异性合并症指数≥3、HLA不合或单倍体供者、脐带血、体内T细胞去除、2005至2009年移植、急性和慢性GVHD。
核心结论
- HCT后AdV病仍是临床挑战,现有抗病毒药物改善率和生存率欠佳,需要更好的抗病毒手段。
研究设计与样本
- 日本登记数据库分析,纳入2005至2019年接受自体HCT的25233例和异基因HCT的48380例患者,评估AdV病的累积发病率、危险因素、生存和治疗详情。
主要发现
- 1年AdV病累积发病率:儿童自体HCT为0.18%、异基因HCT为1.52%;成人自体HCT为0.49%、异基因HCT为2.99%。
- AdV病患者中最常见表现为肾尿路感染;菌血症或播散性疾病在自体HCT后占6%、异基因HCT后占19%。
- 多因素分析显示,自体HCT后AdV病与年龄≥50岁和淋巴瘤相关。
- 异基因HCT后AdV病与年龄≥50岁、男性、淋巴瘤、HCT特异性合并症指数≥3、HLA不合或单倍体供者、脐带血、体内T细胞去除、2005至2009年移植、急性GVHD和慢性GVHD相关。
- AdV病诊断后1年生存概率:自体HCT为65%,异基因HCT为44%;无论AdV疾病负担如何,自体及异基因HCT后死亡风险均增加。
关键数值与推荐
- 最常用抗病毒药物为西多福韦和阿糖腺苷;现有药物改善率和生存概率欠佳。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We analyzed a Japanese registry database to elucidate the incidence, risk factors, and outcomes of adenovirus (AdV) disease after autologous and allogeneic hematopoietic cell transplantation (HCT) in contemporary real-world patients. We evaluated the cumulative incidence of AdV disease, as well as risk factors, survival, and treatment details, among 25 233 patients who underwent autologous HCT and 48 380 patients who underwent allogeneic HCT between 2005 and 2019. The 1-year cumulative incidences of AdV disease after autologous and allogeneic HCT were 0.18% and 1.52%, respectively, in children, and 0.49% and 2.99%, respectively, in adults. Among patients with AdV disease, renourinary infection was the most common manifestation, and viremia or disseminated disease occurred in 6% of those after autologous HCT and 19% of those after allogeneic HCT. In multivariate analysis, age ≥50 years and lymphoma were associated with AdV disease after autologous HCT, while patients age ≥50 years, male patients, lymphoma, HCT-specific comorbidity index ≥3, human leukocyte antigen-mismatched or haploidentical donors, cord blood, in vivo T-cell depletion, HCT from 2005 to 2009, acute graft-versus-host disease (GVHD), and chronic GVHD were associated with AdV disease after allogeneic HCT. The 1-year probabilities of survival after disease diagnosis were 65% in autologous HCT and 44% in allogeneic HCT. Regardless of the AdV disease burden, there was an increased risk of mortality after both autologous and allogeneic HCT. The most commonly used antiviral agents were cidofovir and vidarabine. The probabilities of improvement and survival with currently available agents were suboptimal. AdV disease after HCT remains a challenge. Better antiviral modalities are necessary.
引用
- Inamoto Y, Takeda W, Hirakawa T, et al. Adenovirus disease after hematopoietic cell transplantation: A Japanese transplant registry analysis. Am J Hematol. 2022. PMID: 36087061. doi:10.1002/ajh.26723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。